The development of anti-PD-1 antibody-induced spinal cord injury in bone marrow transplant C57BL/6 Rag1^-/- mouse model

References

• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454. doi:10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218. doi:10.1038/nature12213
   PubMed Web of Science ®Google Scholar
• Seidel JA, Otsuka A, Kabashima K, et al. Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy and limitations. Front Oncol. 2018;8:86. doi:10.3389/fonc.2018.00086
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887–3895. doi:10.1002/j.1460-2075.1992.tb05481.x
   PubMed Web of Science ®Google Scholar
• Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141–151. doi:10.1016/S1074-7613(00)80089-8
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–168. doi:10.1056/NEJMra1703481
   PubMed Web of Science ®Google Scholar
• Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767–1778. doi:10.1056/NEJMra1514296
   PubMed Web of Science ®Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2023;41:943–954. doi:10.1200/JCO.22.02272
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330. doi:10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257–265. doi:10.1016/S1470-2045(15)70054-9
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532. doi:10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–2028. doi:10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34:2460–2467. doi:10.1200/JCO.2015.64.8931
   PubMed Web of Science ®Google Scholar
• O'Donnell PH, Plimack ER, Bellmunt J, et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: results of a phase IB study. J Clin Oncol. 2015;33:296–296. doi:10.1200/jco.2015.33.7_suppl.296
   Google Scholar
• Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018;29:250–255. doi:10.1093/annonc/mdx642
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–1755. doi:10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–1728. doi:10.1001/jamaoncol.2018.3923
   PubMed Web of Science ®Google Scholar
• Basso DM, Fisher LC, Anderson AJ, et al. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma. 2006;23:635–659. doi:10.1089/neu.2006.23.635
   PubMed Web of Science ®Google Scholar
• Fischer AH, Jacobson KA, Rose J, et al. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008;1:pdb.prot4986. doi:10.1101/pdb.prot4986
   Google Scholar
• Mombaerts P, Iacomini J, Johnson RS, et al. RAG-1-deficient mice have no mature B and T lymphocytes. Cell. 1992;68:869–877. doi:10.1016/0092-8674(92)90030-G
   PubMed Web of Science ®Google Scholar
• Raja SM, Metkar SS, Froelich CJ. Cytotoxic granule-mediated apoptosis: unraveling the complex mechanism. Curr Opin Immunol. 2003;15:528–532. doi:10.1016/S0952-7915(03)00111-0
   PubMed Web of Science ®Google Scholar
• Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford). 2006;45:26–30. doi:10.1093/rheumatology/kei113
   PubMed Web of Science ®Google Scholar
• Sun J, Bird CH, Sutton V, et al. A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem. 1996;271:27802–27809. doi:10.1074/jbc.271.44.27802
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714–1768. doi:10.1200/JCO.2017.77.6385
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics and immunologic correlates. J Clin Oncol. 2010;28:3167–3175. doi:10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi F, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). J Clin Oncol Official J Am Soc Clin Oncol. 2014;32:LBA9000. doi:10.1200/jco.2014.32.18_suppl.lba9000
   Google Scholar
• Carmona LM, Schatz DG. New insights into the evolutionary origins of the recombination-activating gene proteins and V(D)J recombination. FEBS J. 2017;284:1590–1605. doi:10.1111/febs.13990
   PubMed Web of Science ®Google Scholar
• Ott de Bruin L, Yang W, Capuder K, et al. Rapid generation of novel models of RAG1 deficiency by CRISPR/Cas9-induced mutagenesis in murine zygotes. Oncotarget. 2016;7:12962–12974. doi:10.18632/oncotarget.7341
   PubMedGoogle Scholar
• van Til NP, de Boer H, Mashamba N, et al. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene. Mol Ther. 2012;20:1968–1980. doi:10.1038/mt.2012.110
   PubMed Web of Science ®Google Scholar
• He D, Zhang J, Wu W, et al. A novel immunodeficient rat model supports human lung cancer xenografts. FASEB J. 2019;33:140–150. doi:10.1096/fj.201800102RR
   PubMed Web of Science ®Google Scholar
• Weckbach S, Neher M, Losacco JT, et al. Challenging the role of adaptive immunity in neurotrauma: rag1(-/-) mice lacking mature B and T-cells do not show neuroprotection after closed head injury. J Neurotrauma. 2012;29:1233–1242. doi:10.1089/neu.2011.2169
   PubMed Web of Science ®Google Scholar
• Yu W, Sun J, Wang T, et al. The effect of microwave ablation combined with anti-PD-1 monoclonal antibody on T cell subsets and long-term prognosis in patients suffering from non-small-cell lung cancer. Comput Math Methods Med. 2022;2022:7095423. doi:10.1155/2022/7095423
   PubMedGoogle Scholar
• Zhang Y, Zhu T, Wang Q, et al. Effects of PD-1 inhibitor combined with anti-angiogenic drugs on efficacy and immune function of non-small cell lung cancer. Am J Transl Res. 2022;14:8225–8233.
   PubMed Web of Science ®Google Scholar
• Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2014;112:24–49. doi:10.1016/j.pneurobio.2013.10.004
   PubMed Web of Science ®Google Scholar
• Zhang N, Yin Y, Xu SJ, et al. Inflammation & apoptosis in spinal cord injury. Indian J Med Res. 2012;135:287–296.
   PubMed Web of Science ®Google Scholar
• Abrahams VM, Kamsteeg M, Mor G. The Fas/Fas ligand system and cancer: immune privilege and apoptosis. Mol Biotechnol. 2003;25:19–30. doi:10.1385/MB:25:1:19
   PubMed Web of Science ®Google Scholar
• Mustafa N, Mitxelena J, Infante A, et al. E2f2 attenuates apoptosis of activated T lymphocytes and protects from immune-mediated injury through repression of Fas and FasL. Int J Mol Sci. 2021;23:311. doi:10.3390/ijms23010311
   PubMed Web of Science ®Google Scholar
• Barrie MB, Stout HW, Abougergi MS, et al. Antiviral cytokines induce hepatic expression of the granzyme B inhibitors, proteinase inhibitor 9 and serine proteinase inhibitor 6. J Immunol. 2004;172:6453–6459. doi:10.4049/jimmunol.172.10.6453
   PubMed Web of Science ®Google Scholar
• Cunningham TD, Jiang X, Shapiro DJ. Expression of high levels of human proteinase inhibitor 9 blocks both perforin/granzyme and Fas/Fas ligand-mediated cytotoxicity. Cell Immunol. 2007;245:32–41. doi:10.1016/j.cellimm.2007.03.004
   PubMed Web of Science ®Google Scholar
• Yepes M, Sandkvist M, Wong MK, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000;96:569–576. doi:10.1182/blood.V96.2.569.014k35_569_576
   PubMed Web of Science ®Google Scholar
• Li Z, Liu F, Zhang L, et al. Neuroserpin restores autophagy and promotes functional recovery after acute spinal cord injury in rats. Mol Med Rep. 2018;17:2957–2963.
   PubMed Web of Science ®Google Scholar
• Ding S, Chen Q, Chen H, et al. The neuroprotective role of neuroserpin in ischemic and hemorrhagic stroke. Curr Neuropharmacol. 2021;19:1367–1378. doi:10.2174/1570159X18666201008113052
   PubMed Web of Science ®Google Scholar